Early mixed T ‐cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant
We examined chimerism trends post‐HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T‐cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T‐cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T‐cell chimerism may warrant closer disease monitoring and consideration for early intervention.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Larisa Broglie, Irene Helenowski, Lawrence J. Jennings, Kristian Schafernak, Reggie Duerst, Jennifer Schneiderman, William Tse, Morris Kletzel, Sonali Chaudhury Tags: Brief Report Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Children | Chronic Leukemia | Legislation | Leukemia | Myelodysplastic Syndrome | Pediatrics | Stem Cell Therapy | Stem Cells | Transplants